Public Sector Pension Investment Board lessened its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 50.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 199,902 shares of the biopharmaceutical company's stock after selling 203,673 shares during the period. Public Sector Pension Investment Board's holdings in Gilead Sciences were worth $29,554,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in the company. Global Retirement Partners LLC increased its position in Gilead Sciences by 4.8% during the 3rd quarter. Global Retirement Partners LLC now owns 36,269 shares of the biopharmaceutical company's stock worth $5,406,000 after purchasing an additional 1,665 shares in the last quarter. BCGM Wealth Management LLC increased its holdings in Gilead Sciences by 10.0% in the 3rd quarter. BCGM Wealth Management LLC now owns 15,950 shares of the biopharmaceutical company's stock worth $2,377,000 after purchasing an additional 1,447 shares in the last quarter. Rothschild Investment LLC raised its position in Gilead Sciences by 17.8% in the third quarter. Rothschild Investment LLC now owns 6,190 shares of the biopharmaceutical company's stock valued at $923,000 after purchasing an additional 935 shares during the last quarter. Tradewinds LLC. boosted its stake in shares of Gilead Sciences by 841.6% during the third quarter. Tradewinds LLC. now owns 4,435 shares of the biopharmaceutical company's stock valued at $661,000 after purchasing an additional 3,964 shares in the last quarter. Finally, Ironwood Investment Counsel LLC increased its stake in shares of Gilead Sciences by 12.5% in the third quarter. Ironwood Investment Counsel LLC now owns 3,567 shares of the biopharmaceutical company's stock valued at $532,000 after buying an additional 396 shares during the period. 83.67% of the stock is currently owned by institutional investors and hedge funds.
Gilead Sciences Trading Down 1.4%
NASDAQ:GILD opened at $166.53 on Friday. The company has a debt-to-equity ratio of 1.84, a current ratio of 1.38 and a quick ratio of 1.22. Gilead Sciences, Inc. has a one year low of $116.88 and a one year high of $176.58. The company has a market cap of $206.55 billion, a PE ratio of -52.70 and a beta of 0.35. The firm has a 50-day moving average of $156.80 and a 200-day moving average of $142.34.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. The business had revenue of $8.30 billion for the quarter, compared to analysts' expectations of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm's revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter last year, the firm earned $2.47 EPS. As a group, equities research analysts expect that Gilead Sciences, Inc. will post -0.97 EPS for the current fiscal year.
Gilead Sciences Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Stockholders of record on Tuesday, December 15th will be issued a $0.82 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 annualized dividend and a dividend yield of 2.0%. Gilead Sciences's dividend payout ratio is currently -103.80%.
Insider Activity
In other Gilead Sciences news, EVP Wettan Keeley M. Cain sold 3,399 shares of the company's stock in a transaction on Friday, November 6th. The stock was sold at an average price of $164.11, for a total value of $557,809.89. Following the completion of the transaction, the executive vice president owned 5,360 shares in the company, valued at $879,629.60. This represents a 38.81% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $170.55, for a total transaction of $4,775,400.00. Following the completion of the transaction, the insider directly owned 110,684 shares in the company, valued at $18,877,156.20. This trade represents a 20.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 237,709 shares of company stock valued at $39,799,137 over the last ninety days. Company insiders own 0.30% of the company's stock.
Analysts Set New Price Targets
Several brokerages recently weighed in on GILD. Royal Bank Of Canada boosted their price objective on shares of Gilead Sciences from $126.00 to $131.00 and gave the stock a "sector perform" rating in a research note on Friday, October 30th. Needham & Company LLC set a $175.00 target price on Gilead Sciences in a report on Friday, October 30th. BMO Capital Markets restated an "outperform" rating and issued a $184.00 price target on shares of Gilead Sciences in a research report on Friday, October 30th. UBS Group boosted their price objective on Gilead Sciences from $175.00 to $195.00 and gave the company a "buy" rating in a research note on Friday, October 30th. Finally, Citigroup lifted their target price on Gilead Sciences from $165.00 to $188.00 and gave the stock a "buy" rating in a report on Friday, October 30th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences has a consensus rating of "Moderate Buy" and an average price target of $171.63.
View Our Latest Research Report on GILD
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.
Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.